UCB S.A. UNSP.ADR 1/2 Total Liabilities
UCB S.A. UNSP.ADR 1/2 total liabilities. Based on the latest financial reports, UCB S.A. UNSP.ADR 1/2 (UNC0) has total liabilities worth €8.98 Billion EUR (≈ $10.50 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check UCB S.A. UNSP.ADR 1/2 (UNC0) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of UCB S.A. UNSP.ADR 1/2 (2021–2025)
Total liabilities of UCB S.A. UNSP.ADR 1/2 from 2021 to 2025. This chart illustrates how UCB S.A. UNSP.ADR 1/2's total liabilities have evolved over time, based on quarterly financial data.
UCB S.A. UNSP.ADR 1/2 Competitors by Total Liabilities
The table below lists competitors of UCB S.A. UNSP.ADR 1/2 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Commerzbank AG
F:ZZMS
|
Germany | €583.62 Billion |
|
Cheniere Energy Inc
NYSE MKT:LNG
|
USA | $33.64 Billion |
|
Ambev S.A
MX:ABEVN
|
Mexico | MX$48.03 Billion |
|
Astera Labs, Inc.
NASDAQ:ALAB
|
USA | $205.80 Million |
|
Woodside Energy Group Ltd
AU:WDS
|
Australia | AU$26.68 Billion |
|
Fifth Third Bancorp
NASDAQ:FITB
|
USA | $262.93 Billion |
|
BASF SE
XETRA:BAS
|
Germany | €46.47 Billion |
|
Ambev S.A.
SA:ABEV3
|
Brazil | R$54.79 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down UCB S.A. UNSP.ADR 1/2's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see UNC0 total asset value.
Liquidity & Leverage Metrics
UCB S.A. UNSP.ADR 1/2 Total Liabilities Ratios Explained
UCB S.A. UNSP.ADR 1/2 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how UCB S.A. UNSP.ADR 1/2's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for UCB S.A. UNSP.ADR 1/2 (2021–2025)
The table below shows the annual total liabilities of UCB S.A. UNSP.ADR 1/2 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €7.29 Billion ≈ $8.52 Billion |
-0.37% |
| 2024-12-31 | €7.32 Billion ≈ $8.56 Billion |
+11.49% |
| 2023-12-31 | €6.56 Billion ≈ $7.67 Billion |
-3.53% |
| 2022-12-31 | €6.80 Billion ≈ $7.95 Billion |
+16.83% |
| 2021-12-31 | €5.82 Billion ≈ $6.81 Billion |
-- |
About UCB S.A. UNSP.ADR 1/2
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthr… Read more